Introduction
Cardiovascular disease is one of the leading causes of death, especially in developed countries. Several modifiable risk factors for cardiovascular disease have now been well established, especially cigarette smoking, hypertension, and elevated plasma cholesterol. Pharmacotherapeutic interventions, such as the use of aspirin and other antithrombotic drugs, antihypertensive drugs, and cholesterol-lowering therapy, have contributed in part to the gradual decline in cardiovascular deaths over the past few decades [1, 2] . Statins are inhibitors of 3-hydroxy-3methylglutaryl coenzyme A (HMG CoA) reductase, which inhibits cholesterol production in the hepatocyte, which in turn increases the synthesis of low-density lipoprotein (LDL) receptors and thereby lowers blood cholesterol levels. In recent years, at least eight landmark trials have been published that establish the efficacy of statin therapy in primary and secondary prevention [3] [4] [5] [6] [7] [8] [9] [10] . Treatment with statins over a 5-year period was associated with a statistically significant reduction in mortality and in the number of patients experiencing a heart attack or a stroke, or undergoing a revascularization procedure. Overall, the risk reduction for coronary artery disease for subjects using statins was approximately 27% [11] . These reductions, however, are average effects for all patients included in the trials. There is notable interindividual variation in response to statins, and the origins of this variation are poorly understood.
Pharmacogenetics
Pharmacogenetics and pharmacogenomics are emerging disciplines that focus on genetic determinants of drug response at the levels of single genes or the entire human genome, respectively [12] . Although pharmacogenetics is not a new field, it has recently enjoyed a surge in activity as a result of the availability of better tools and a realization of potential benefit by both the pharmaceutical industry and government regulatory bodies. The applied objectives of pharmacogenetics include improving drug efficacy, avoiding harmful side effects, and improving the efficiency and timeliness of drug response.
Several reviews on the pharmacogenetics of statins have been published [13,14••,15,16] . Both the effects on cholesterol levels and on cardiovascular event response have been described. These effects might be different because statins have certain effects that are independent of cholesterol lowering, such as effects on blood pressure, coagulation, cell proliferation, immune function, and macrophage metabolism [17, 18] . Importantly for statins, the effects on cholesterol levels alone may not accurately predict the effects on cardiovascular morbidity and mortality [19] . Although the initial focus of pharmacogenetics was on drug-metabolizing pathways (ie, pharmacokinetics), more recently the focus has shifted to the genetic basis of individual variation of drug efficacy (ie, pharmacodynamics). Although statins are highly metabolized by the liver and the cytochrome Pharmacogenetics of Response to Statins: Where Do We Stand? Maitland-van der Zee and Boerwinkle 205 P450 enzyme system, the published literature on pharmacogenetics concerning statin response is dominated by pharmacodynamics. The results of several such studies are reviewed in the following text.
Results
In subjects with primary hypercholesterolemia, 23 studies have examined the effects of genetic polymorphisms (or their combinations) at 20 different loci on the lipid response to statin treatment, and 18 studies have examined genetic polymorphisms involved in the benefits of statin therapy in the prevention of atherosclerotic cardiovascular disease [14••] . Even though many studies have been performed, few results have been replicated. Hirschhorn et al. [20••] provide an insightful discussion on the possible reasons why genetic association results may not be replicated by other association studies.
In this review, we do not provide an exhaustive summary of genetic association studies for response to statins. Rather, we restrict our analysis to genes that have been studied in at least two different study populations (Table 1 ). The genes that are studied more than once are apolipoprotein E (ApoE) (the 2/3/4 polymorphism), the LDL receptor (AvaII, HincII, and PvuII polymorphisms), APOB (insertion/deletion polymorphism), cholesteryl ester transfer protein (CETP; the TaqIB polymorphism), hydroxy-methylglutaryl coenzyme A reductase (HMGCR; different single nucleotide polymorphisms [SNPs]), and the angiotensin-converting enzyme (ACE; insertion/ deletion polymorphism). Only the interaction between the ApoE gene and the cholesterol-lowering effect of statins was found in more than one study. Even for this wellstudied gene, four out of eight studies were not able to show a significant interaction between the gene variation and statin treatment on the study outcome. This is the case for both LDL cholesterol response and risk reduction. In the cases of ACE and CETP, not only could the interaction not be replicated, but opposite effects were found. Kuivenhoven et al. [21] found that subjects with the B2B2 genotype had no beneficial effect from statins on reducing mean segment diameter, whereas Carlquist et al. [22] concluded that subjects with the B1B2 and B2B2 genotype had the most beneficial effect from statins on reducing the amount of clinical events. In the study by Bray et al. [23] , ACE D carriers had a larger risk reduction than ACE II subjects, whereas in the observational study by Maitland-van der Zee et al.
[24], men with the ACE II genotype had the best risk-reducing effect of statins.
In the pharmacogenetics of statins as in other pharmacogenetic studies, there are multiple reasons why different association studies can report different results, and these reasons may be acting simultaneously when comparing any two studies.
First, the results of an association study depend on the outcome being analyzed, and different outcomes have been used by different studies (eg, cholesterol-lowering effect, effect on mean segment diameter, effect on reducing frequency of clinical events). Second, the results may depend on the population sampled and the study design. Populations differ in allele frequencies at most genes, and there may be differences in the role of other (not studies) genetic, environmental, and social influences. Also, pharmacogenetic studies may or may not include a placebo arm, and the comparison groups are often complex [25] . Third, different results may be found because of differences in the statin that was used. The various statin drugs are known to have different effects [26] , and there are possibly different responses across the different statins. Lastly, the sample sizes of many pharmacogenetic studies may not be sufficiently large in light of the likely small effects expected of common genetic variation. There is an unsupported expectation in both the scientific community and the public-at-large that single nucleotide variation 
